GLPwatch
The evolving world of GLP-1 agonist therapies for type 2 diabetes.
Ther Adv Endocrinol Metab · 2010
Last updated 2026-05-28GLP-1 drugs help people with type 2 diabetes by improving blood sugar control, with studies showing a reduction of 0.8% to 1.1% in HbA1c levels. They also lead to some weight loss and work by increasing insulin, reducing glucagon, slowing digestion, and decreasing food intake. While their short- to medium-term safety is well known, long-term safety data is not yet available.
AI summary of the abstract below.
| Journal | Ther Adv Endocrinol Metab, 2010 |
|---|---|
| Citations | 3 |
| Relative citation ratio | 0.07 |
| NIH percentile | 6 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
The glucagon-like peptide-1 (GLP-1) agonist drugs have attractions as a treatment for type 2 diabetes since they positively alter a number of key pathophysiological defects. These include increasing insulin release, reducing glucagon release, slowing gastric emptying and reducing food intake. In numerous clinical trials these agents have been shown to reduce DCCT-aligned HbA(1c) between 0.8% and 1.1% in patients with moderately controlled type 2 diabetes, whilst also being associated with some weight loss. Whilst medium-term safety and side-effect profiles are now well established, there are as yet no long-term studies on the safety of this group of drugs. The place of the GLP-1 agonists in the treatment paradigm for type 2 diabetes will evolve over the next decade.
Verbatim abstract via PubMed 23148151 ↗